What is Entrectinib used for?

Introduction to Entrectinib:
Entrectinib, known by the trade names Rozlytrek and RXDX-101, is a groundbreaking drug in the field of oncology. It is an oral, small-molecule tyrosine kinase inhibitor (TKI) developed primarily by Ignyta, Inc., a biotechnology company that was later acquired by Roche. Entrectinib is specifically designed to target and inhibit key proteins involved in the growth and proliferation of cancer cells. These targets include tropomyosin receptor kinases (TRK) such as TRKA, TRKB, and TRKC, as well as ROS1 and ALK (anaplastic lymphoma kinase).

This drug has been approved for use in the treatment of specific types of solid tumors that harbor NTRK gene fusions (a type of genetic alteration) and ROS1-positive metastatic non-small cell lung cancer (NSCLC). The indication for its use was based on its ability to shrink tumors in patients with these genetic abnormalities, providing a new targeted therapy option for individuals whose cancers have the relevant mutations. Clinical trials such as ALKA-372-001, STARTRK-1, and STARTRK-2 have been pivotal in assessing the efficacy and safety of entrectinib, leading to regulatory approvals in various countries, including the United States and the European Union.

Entrectinib Mechanism of Action:
Entrectinib works by targeting and inhibiting specific tyrosine kinases that are abnormally activated due to genetic mutations or rearrangements in cancer cells. These kinases include TRKA, TRKB, TRKC, ROS1, and ALK. In normal cells, these kinases play a role in signaling pathways that regulate cell growth, survival, and differentiation. However, in cancer cells with NTRK gene fusions or ROS1/ALK rearrangements, these kinases become constitutively active, driving uncontrolled cell proliferation and tumor growth.

By binding to the ATP-binding site of these tyrosine kinases, entrectinib blocks their activity, thereby inhibiting downstream signaling pathways that promote cancer cell survival and proliferation. This inhibition leads to tumor cell death and a reduction in tumor size. Importantly, entrectinib is designed to cross the blood-brain barrier, making it effective against primary and metastatic brain tumors that harbor these genetic alterations.

How to Use Entrectinib:
Entrectinib is administered orally, typically in the form of capsules. The standard recommended dosage is 600 mg once daily, taken with or without food. It is crucial to swallow the capsules whole without crushing, chewing, or dissolving them. The drug is absorbed through the gastrointestinal tract and reaches peak plasma concentrations within four to six hours post-administration.

The onset of action varies, with some patients experiencing clinical benefits, such as tumor shrinkage or symptom relief, within a few weeks of starting treatment. However, the full therapeutic effect may take several months to become evident. The duration of treatment with entrectinib depends on the patient's response to therapy and the presence of side effects. Continuous monitoring through imaging studies and clinical assessments is essential to evaluate the drug's efficacy and adjust the treatment plan as needed.

What is Entrectinib Side Effects:
Like all medications, entrectinib comes with a range of potential side effects, some of which can be serious. Common side effects include fatigue, constipation, dysgeusia (altered taste), edema, dizziness, and weight gain. Gastrointestinal symptoms such as nausea, vomiting, and diarrhea are also frequently reported. Patients may experience increased levels of liver enzymes, indicating potential liver dysfunction, which necessitates regular liver function tests.

Serious side effects are less common but can occur. These include heart problems, such as congestive heart failure and QT prolongation (a heart rhythm condition that can lead to serious arrhythmias). CNS effects are notable, given entrectinib's ability to cross the blood-brain barrier, and can include cognitive impairment, mood changes, and gait disturbances. Hyperuricemia (elevated uric acid levels) and bone fractures have also been reported in some patients.

Contraindications for the use of entrectinib include known hypersensitivity to the drug or any of its components. Caution is advised in patients with pre-existing cardiac conditions, hepatic impairment, or those who are pregnant or breastfeeding, as entrectinib can cause fetal harm. Patients should be closely monitored for the emergence of side effects, and dose adjustments or discontinuation may be necessary based on the severity of adverse reactions.

What Other Drugs Will Affect Entrectinib:
Entrectinib is metabolized primarily by the cytochrome P450 enzyme CYP3A4. Therefore, drugs that strongly inhibit or induce this enzyme can significantly affect the plasma concentration of entrectinib. Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) can increase entrectinib levels, potentially leading to enhanced side effects. Conversely, strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) can decrease entrectinib levels, reducing its efficacy.

Additionally, entrectinib can affect other medications metabolized by CYP3A4, potentially altering their effectiveness or increasing their toxicity. Patients should inform their healthcare providers of all medications they are taking, including over-the-counter drugs, supplements, and herbal products, to avoid harmful interactions.

Since entrectinib can prolong the QT interval, caution should be exercised when it is used in combination with other QT-prolonging drugs (e.g., certain antiarrhythmics, antipsychotics, and antibiotics). The combined use of such drugs can increase the risk of life-threatening arrhythmias.

In summary, entrectinib represents a significant advancement in targeted cancer therapy, offering hope to patients with specific genetic mutations. Its mechanism of action, administration guidelines, potential side effects, and drug interactions should be carefully considered to maximize its therapeutic benefits while minimizing risks.